Clinical Trial Detail

NCT ID NCT03138499
Title Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin

Brentuximab vedotin + Nivolumab

Age Groups: adult senior

No variant requirements are available.